Funding progress at PCF

Companies: PCF   
28/10/2008

Private & Commercial Finance Group (PCF) has achieved half its £15 million two-year funding target in six months.

Scott Maybury, newly installed as chief executive of the AIM quoted company, says it has raised £7.5 million since April from the likes of Hitachi Capital and Siemens Finance. London-based PCF, which recently forecast a sdsys15 per cent first-half profits increase, does not expect to repeat last year’s 40 per cent portfolio growth and sees 7 to 8 per cent as more realistic in today’s markets, though with higher margins.

PCF, which has 20,000 outstanding loan agreements worth an average £6,500 each and provides equipment funding for smaller companies and car finance for individuals, is now operating in a market where demand exceeds supply, says Maybury. Companies and private individuals alike are trying to reduce their borrowing, but rival lenders are also pulling out, leaving PCF with ‘a larger share of a smaller market’.

PCF shares have halved since last year to 12.5p, which analysts argue is less than a third of net asset value. They could offer defensive qualities.

Save 50% off your first year’s subscription to Growth Company Investor magazine, and gain immediate access to all the recommendations online. Click here.

Robert Tyerman

Related Articles:
03/10/2008
01/10/2008
30/09/2008
17/09/2008
29/08/2008

AIM£3.29m 11.50p -1.00p
Other company articles:
03/11/2008
28/10/2008
01/07/2008
13/03/2008
15/01/2008

Sponsored Listings

Looking for Great Saving and Investments? Choose from a variety of the UK's favourite saving and investment specialists. Great deals, low rates and all the latest offers.

Looking for Great Saving and Investments? Choose from a variety of the UK's favourite saving and investment specialists. Great deals, low rates and all the latest offers.

Shares Looking for Shares? Review our comprehensive listings.

Recommendations

Advanced Power Components

SPECULATIVE BUY

Uniq

AVOID

Skyepharma

SPECULATIVE BUY

InterQuest

SPECULATIVE BUY

Ark Therapeutics

SPECULATIVE BUY

Enegi Oil

HOLD

Ted Baker

AVOID

Summit Corporation

SPECULATIVE BUY

London Capital Group

BUY

Sinclair (William) Holdings

BUY
AIM